Limits...
Cross-reactive Antibodies against avian influenza virus A (H5N1).

Pichyangkul S, Jongkaewwattana A, Thitithanyanont A, Ekchariyawat P, Wiboon-ut S, Limsalakpetch A, Yongvanitchit K, Kum-Arb U, Mahanonda R, Utaisincharoen P, Sirisinha S, Mason CJ, Fukuda MM - Emerging Infect. Dis. (2009)

View Article: PubMed Central - PubMed

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Intravenous immunoglobulin (IVIg) is used to treat bacterial and viral infections in patients with primary immunodeficiency disease and those with autoimmune and inflammatory disorders... We tested the efficacy of commercial preparations of IVIg (50 mg/mL of highly purified immunoglobulin) against homosubtypic influenza viruses A (H1N1 and H3N2) and their cross-reactivity against avian influenza virus A (H5N1)... Human Immunoglobulin, pH 4.0, (Harbin Sequel Bio-Engineering Pharmaceutical, Harbin, People’s Republic of China) had lower HI titers against homosubtypic avian influenza viruses (10 for subtype H3N2 and <10 for subtype H1N1)... As expected, we did not detect antibodies against hemagglutinin (HA) of subtype H5N1 (A/open-billed/stork/Nahkonsawan/BBD0104F/2004) in any of the IVIg preparations (HI titer <10)... Octagam and Immunoglobulin, pH 4.0, IVIg were more reactive with M2e of avian influenza virus (H5N1) (A/Thailand/SP-83/2004) than with other M2e peptides... We measured the ability of IVIg preparations to inhibit influenza subtype H5N1 replication by using a plaque-reduction assay... Subtype H5N1 (A/open-billed stork/ Nakhonsawan/BBD0104F/2004) was maintained as described... Although plaques of heterogeneous size were observed in infected plates without IVIg, larger plaques were preferentially neutralized with increasing concentrations of IVIg in the agar (Figure)... Premixing excess M2e peptide with IVIg to absorb M2e-specific antibodies had no effect on plaque formation, indicating that antibodies against M2e in IVIg preparations were not responsible for neutralization of influenza subtype H5N1... Our data suggest that the neutralizing activity against influenza subtype H5N1 in all 3 IVIg preparations was likely contributed by cross-reactive antibodies against avian N1... IVIg has been reported to have antiinflammatory activity... The immune suppressive effect of IVIg may benefit patients by reducing the cytokine storm... These data suggest use of IVIg, especially preparations containing high neutralizing activity against subtype H5N1, as adjunctive treatment for infection with highly pathogenic avian influenza virus (H5N1).

Show MeSH

Related in: MedlinePlus

Neutralization of avian influenza virus A (H5N1) by intravenous immunoglobulin (IVIg) preparations measured by percentage reduction in plaque number (A) and plaque size (B). Monolayers of MDCK cells were infected with virus and overlaid with agar containing various concentrations of IVIg. After 2 days, plaques were detected by staining with crystal violet. Shown is a sample of viral plaques with agar overlay containing different dilutions (1:50–1:800) of Human Immunoglobulin, pH 4.0, (Harbin Sequel Bio-Engineering Pharmaceutical, Harbin, People’s Republic of China) IVIg (C). Data are mean ± SE of 3 experiments.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2819863&req=5

Figure 1: Neutralization of avian influenza virus A (H5N1) by intravenous immunoglobulin (IVIg) preparations measured by percentage reduction in plaque number (A) and plaque size (B). Monolayers of MDCK cells were infected with virus and overlaid with agar containing various concentrations of IVIg. After 2 days, plaques were detected by staining with crystal violet. Shown is a sample of viral plaques with agar overlay containing different dilutions (1:50–1:800) of Human Immunoglobulin, pH 4.0, (Harbin Sequel Bio-Engineering Pharmaceutical, Harbin, People’s Republic of China) IVIg (C). Data are mean ± SE of 3 experiments.

Mentions: We measured the ability of IVIg preparations to inhibit influenza subtype H5N1 replication by using a plaque-reduction assay. Subtype H5N1 (A/open-billed stork/ Nakhonsawan/BBD0104F/2004) was maintained as described (8). MDCK cells were infected with virus and agar containing various concentrations of IVIg was layered on top of these cells and incubated for 2 days. Results are shown in the Figure. IVIG inhibited plaque formation in a dose-dependent manner. Although plaques of heterogeneous size were observed in infected plates without IVIg, larger plaques were preferentially neutralized with increasing concentrations of IVIg in the agar (Figure).


Cross-reactive Antibodies against avian influenza virus A (H5N1).

Pichyangkul S, Jongkaewwattana A, Thitithanyanont A, Ekchariyawat P, Wiboon-ut S, Limsalakpetch A, Yongvanitchit K, Kum-Arb U, Mahanonda R, Utaisincharoen P, Sirisinha S, Mason CJ, Fukuda MM - Emerging Infect. Dis. (2009)

Neutralization of avian influenza virus A (H5N1) by intravenous immunoglobulin (IVIg) preparations measured by percentage reduction in plaque number (A) and plaque size (B). Monolayers of MDCK cells were infected with virus and overlaid with agar containing various concentrations of IVIg. After 2 days, plaques were detected by staining with crystal violet. Shown is a sample of viral plaques with agar overlay containing different dilutions (1:50–1:800) of Human Immunoglobulin, pH 4.0, (Harbin Sequel Bio-Engineering Pharmaceutical, Harbin, People’s Republic of China) IVIg (C). Data are mean ± SE of 3 experiments.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2819863&req=5

Figure 1: Neutralization of avian influenza virus A (H5N1) by intravenous immunoglobulin (IVIg) preparations measured by percentage reduction in plaque number (A) and plaque size (B). Monolayers of MDCK cells were infected with virus and overlaid with agar containing various concentrations of IVIg. After 2 days, plaques were detected by staining with crystal violet. Shown is a sample of viral plaques with agar overlay containing different dilutions (1:50–1:800) of Human Immunoglobulin, pH 4.0, (Harbin Sequel Bio-Engineering Pharmaceutical, Harbin, People’s Republic of China) IVIg (C). Data are mean ± SE of 3 experiments.
Mentions: We measured the ability of IVIg preparations to inhibit influenza subtype H5N1 replication by using a plaque-reduction assay. Subtype H5N1 (A/open-billed stork/ Nakhonsawan/BBD0104F/2004) was maintained as described (8). MDCK cells were infected with virus and agar containing various concentrations of IVIg was layered on top of these cells and incubated for 2 days. Results are shown in the Figure. IVIG inhibited plaque formation in a dose-dependent manner. Although plaques of heterogeneous size were observed in infected plates without IVIg, larger plaques were preferentially neutralized with increasing concentrations of IVIg in the agar (Figure).

View Article: PubMed Central - PubMed

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Intravenous immunoglobulin (IVIg) is used to treat bacterial and viral infections in patients with primary immunodeficiency disease and those with autoimmune and inflammatory disorders... We tested the efficacy of commercial preparations of IVIg (50 mg/mL of highly purified immunoglobulin) against homosubtypic influenza viruses A (H1N1 and H3N2) and their cross-reactivity against avian influenza virus A (H5N1)... Human Immunoglobulin, pH 4.0, (Harbin Sequel Bio-Engineering Pharmaceutical, Harbin, People’s Republic of China) had lower HI titers against homosubtypic avian influenza viruses (10 for subtype H3N2 and <10 for subtype H1N1)... As expected, we did not detect antibodies against hemagglutinin (HA) of subtype H5N1 (A/open-billed/stork/Nahkonsawan/BBD0104F/2004) in any of the IVIg preparations (HI titer <10)... Octagam and Immunoglobulin, pH 4.0, IVIg were more reactive with M2e of avian influenza virus (H5N1) (A/Thailand/SP-83/2004) than with other M2e peptides... We measured the ability of IVIg preparations to inhibit influenza subtype H5N1 replication by using a plaque-reduction assay... Subtype H5N1 (A/open-billed stork/ Nakhonsawan/BBD0104F/2004) was maintained as described... Although plaques of heterogeneous size were observed in infected plates without IVIg, larger plaques were preferentially neutralized with increasing concentrations of IVIg in the agar (Figure)... Premixing excess M2e peptide with IVIg to absorb M2e-specific antibodies had no effect on plaque formation, indicating that antibodies against M2e in IVIg preparations were not responsible for neutralization of influenza subtype H5N1... Our data suggest that the neutralizing activity against influenza subtype H5N1 in all 3 IVIg preparations was likely contributed by cross-reactive antibodies against avian N1... IVIg has been reported to have antiinflammatory activity... The immune suppressive effect of IVIg may benefit patients by reducing the cytokine storm... These data suggest use of IVIg, especially preparations containing high neutralizing activity against subtype H5N1, as adjunctive treatment for infection with highly pathogenic avian influenza virus (H5N1).

Show MeSH
Related in: MedlinePlus